The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects

The use of immunotherapy to treat cancer is rapidly gaining momentum. Using pre-clinical mouse models, we have recently demonstrated potent and long lasting tumor regression can be elicited by immune-stimulating monoclonal antibodies (mAbs) when combined with histone deacetylase inhibitors (HDACi) a...

Descripción completa

Detalles Bibliográficos
Autores principales: West, Alison C., Christiansen, Ailsa J., Smyth, Mark J., Johnstone, Ricky W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382866/
https://www.ncbi.nlm.nih.gov/pubmed/22737621
http://dx.doi.org/10.4161/onci.18804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382866/
https://www.ncbi.nlm.nih.gov/pubmed/22737621
http://dx.doi.org/10.4161/onci.18804

Ejemplares similares